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Abstract
Background: High-Density Lipoprotein (HDL), one of the main plasma lipoproteins, serves as a
docking station for proteins involved in inflammation, coagulation, and lipid metabolism.
Methods: To elucidate the protein composition of HDL, we employed SELDI-TOF mass
spectrometry as a potential high-throughput proteomic candidate for protein profiling of HDL.
HDL derived from normolipemic individuals was captured on PS20 protein-chips using covalently
bound antibodies against apo A-I or A-II.
Results: After optimisation, on-chip capture of HDL particles directly from plasma or from pre-
purified HDL resulted in comparable fingerprints confirming specific capture of HDL. Depending
on the capture antibody some differences in the fingerprint were observed. The most detailed
fingerprint was observed up to 50 kDa; approximately 95 peaks were detected in the 3–50 kDa
molecular mass range. Between 50 and 160 kDa, 27 more peaks were detected.
Conclusion: Based on these results, SELDI-TOF MS may be a suitable high-throughput candidate
for HDL protein profiling and marker search. This approach may be used to i) investigate the
underlying mechanisms that lead to increased atherothrombotic risk and ii) to investigate the
atherothrombotic state of an individual.
Background
Vascular disease, and particularly atherothrombotic dis-
ease, is one of the major causes of death worldwide. Dys-
lipidemia, one of the primary risk factors of
atherosclerosis, is characterized by elevated levels of ather-
ogenic lipoproteins (chylomicron remnants, very low-
density lipoprotein (VLDL) and low-density lipoprotein
(LDL)). In contrast, high-density lipoprotein (HDL) is
inversely associated with the risk for cardiovascular dis-
ease [1].
Intensive research over the past decade has elucidated the
involvement of multiple pathways in atherogenesis, such
as a long-term inflammatory and immune responses
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HDL, coagulation and fibrinolysis [4-6]. Key markers of
inflammation and the innate immune response include
C-reactive protein (CRP), interleukin-6 (IL-6), tumor
necrosis factor-alpha, and several adhesion molecules [7].
Apart from decreases in the lipid content of HDL upon the
inflammatory reaction [8-10], also the HDL protein com-
position markedly changes during the course of acute
infection and consequent systemic inflammatory
response [11-14]. These modified HDL particles are
known as "acute phase HDL" [2,15-18]. According to the
Ross hypothesis also hemostatic abnormalities contribute
to the hypercoagulable state [19] that may result in a pro-
atherogenic risk profile.
The balance between the HDL protein composition and
the different functions of HDL such as stimulation of
reverse cholesterol transport, antioxidant effects, anti-
inflammatory effects, attenuation of endothelial dysfunc-
tion, reduction of lipoprotein retention and the anti-
thrombotic and profibrinolytic effects may have an
impact on the progress of the atherothrombotic disease.
A proteomic approach covering a broad range of protein
analysis has shown to be a good candidate to address the
HDL protein composition [20-22]. In particular, surface-
enhanced laser desorption ionization time-of flight mass
spectrometry (SELDI-TOF MS) employs a high-through-
put, sensitive and reproducible method for the analysis of
complex protein mixtures [23,24]. Protein fingerprints
can be achieved after retaining a selection of a complex
protein mixture array by chemical, physical or functional
properties [25,26]. For LDL protein analysis this has
already been established to be a suitable approach [27]
which is for HDL lacking to date.
In this study, we investigated SELDI-TOF MS analysis of
on-chip immuno-captured native HDL particles using
antibodies against apo A-I or apo A-II. We propose that
this method is suitable for screening of HDL or its HDL
sub-populations in the search for biomarkers related to
cardiovascular disease.
Results
In this study SELDI-TOF mass spectrometry was used to
determine protein profiles of HDL associated proteins
directly from plasma. To prevent disturbance of non-HDL
components, an immunocapture procedure was per-
formed using anti-apo A-I or apo-A-II capture antibodies.
Immuno-captured HDL contained no contaminants
when compared to a HDL gel filtration lipid profile of
normal plasma. Especially, no apo B mass could be
detected in immuno-purified HDL in which the same cap-
ture antibodies were used as [28]. As previously shown, 2-
D gel profiles of HDL isolated with the same anti-apo A-I
antibodies revealed a number of proteins that appeared to
be associated with HDL [20,21]. Similar results were
obtained using anti-apo A-II as capturing antibody. These
data demonstrated the feasibility of HDL-immunocaptur-
ing from plasma.
Anti apo A-I and A-II immuno-capture characteristics on a 
SELDI protein chip
The immunocapture procedure was executed on a SELDI
protein chip to allow analysis of HDL bound proteins by
mass spectrometry. Using antibodies against apo A-I or
apo A-II a number of proteins could be visualized by gel
view (Fig. 1). The wash stringency specifically determined
the outcome of the fingerprint (Fig 1, lane 1–4). In the
absence of antibodies on the SELDI chip, non-specific
binding of plasma components was observed. Depending
on the presence of Tween-20 in the final wash step this
non-specific binding was virtually abolished (Fig. 1, lane
4). In the presence of antibodies (Fig. 1, lane 6–8) specific
HDL associated proteins were detected even in the pres-
ence of 0.005 % (v/v) Tween-20. More stringent wash
conditions i.e. high salt or high Tween concentrations
resulted in a complete abolishment of non-specific com-
ponents but also in a reduction of specific markers such as
apo A-I and apo A-II in case of anti A-II or A-I capture
respectively. (not shown). The presence of the 0.005 % (v/
v) Tween-20 in the last wash step appeared to virtually
eliminate non-specific IgG and albumin contamination
Virtual gel-view fingerprints of binding of HDL to a PS20 pro-tein-chipF g re 1
Virtual gel-view fingerprints of binding of HDL to a 
PS20 protein-chip. Lanes 1–4; Non-specific protein binding 
in the absence of specific antibodies (Control) in the pres-
ence of indicated Tween-20 concentrations in the final wash 
step (See materials and methods). Lanes 5–6; HDL capture 
with anti-apo A-I (Lp A-I), Lanes 7–8; HDL capture with 
anti-apo A-II (Lp A-II). The arrows indicate the conditions 
used in all further experiments.
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therefore used in further experiments.
The Intra CVs of the HDL capture was determined using a
plasma pool of more than 200 people. This plasma-pool
had been aliquoted, snap frozen on liquid nitrogen and
stored at -80°C. Intra CVs ranged from 10 to 30 % over
the 3–150 kDa m/z range. The Inter CV range was also
determined in both captures, in the 3–50 kDa range the
inter CVs ranged from 10 to 25 % and in the 50–160 kDa
m/z from 20 to 35 %.
The individual variation (normal variation) was deter-
mined in 20 subjects having normal HDL levels with
respect to apo A-I and cholesterol content. The inter-indi-
vidual CVs were 10 to 35 % in the 3 kDa-10 kDa m/z
range and 15 to 40 % in the 10–150 kDa m/z range.
To investigate the dynamic range of the capture a dilution
series of plasma with apo A-I levels ranging from 1.78
umolar to 23 pmolar were assessed. A decrease of the apo
A-I signal was seen in the range from 14 nmolar to 110
pmolar. The HDL specific pattern virtually did not change
except for the intensity of the peaks. Due to the fully
focussed laser energy to the on-chip coupled IgG, the IgG
specific pattern appeared to be enhanced upon the
decrease of the concentration of HDL. However, in the
setup of the experiments, the chip was saturated with HDL
particles. Similar results were also seen for the anti apo A-
II capture (data not shown).
Specificity of the HDL capture
The protein composition of immuno-captured HDL from
plasma was compared with that of HDL isolated from
plasma by gel filtration (Fig. 2). Both approaches resulted
in comparable fingerprints, indicating that immunocap-
turing of HDL is a good alternative for purification and a
much easier method for scale up.
Next, the specificity of the HDL capture was investigated
by exposing other plasma components to the antibodies
on the immuno-capture chip. Hardly any signal was
observed when LDL or VLDL was exposed to the SELDI-
chip (Fig. 3). Moreover, exposure of plasma of a Tangier
patient, with known low HDL cholesterol levels [29], still
resulted in HDL specific protein markers although in a
very low abundancy.
Apo A-II isoforms
Apo A-II was visible as a dimer by mass spectrometry.
Upon further inspection, the apo A-II species consisted of
three major isoforms at 17099, 17221 and 17352 M/Z,
respectively (Fig. 4). These isoforms were observed due to
the absence of one or two "end"- terminal glutamine resi-
due per dimer. Each loss of one Gln residue resulted in a
Fingerprints HDL, HDL deficient plasma, LDL and VLDLigu e 3
Fingerprints HDL, HDL deficient plasma, LDL and 
VLDL. All particles were first isolated by gel filtration were 
subjected to SELDI-TOF analysis according to the methods 
as described in the M&M section. Upper and Second 
panel: A spectrum of HDL from a normal subject and HDL 
deficient plasma (Tangier patient having virtually no HDL 
cholesterol [29]). Insert: The cholesterol gel filtration pro-
file of HDL deficient plasma showing only the presence of 
VLDL and LDL and no lipid containing HDL. Third and 
lower panel: LDL and VLDL spectra showing virtually no 
HDL specific pattern.

















































Representative examples of the fingerprint of plasma HDL and pre-purifi d HDL after capture on a PS-20 protein-chipFigur  2
Representative examples of the fingerprint of plasma 
HDL and pre-purified HDL after capture on a PS-20 
protein-chip. Pre-purified HDL (by gel filtration) and 
plasma HDL of the same individual was subjected to SELDI-
TOF analysis according to the conditions as described in the 
materials and methods section. Shown are the fingerprints 
obtained after capture with the indicated monoclonal anti-
bodies against apo A-I (Lp A-I) or apo A-II (Lp A-II).
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idues a decrease of 256 Da was observed (Fig. 4). These
observed M/Z ratios appeared to be in agreement with the
theoretic calculated M/Z's of the three apo A-II isoforms.
Differences between HDL fingerprints after apo A-I or apo 
A-II capture
In figure 5, a typical example of a HDL fingerprint is pre-
sented. The apo A-I (28 kDa) and the dimeric form of apo
A-II (17.4 kDa) clearly recovered in our experimental
setup at the indicated masses. Independent of the use of
the antibodies, both apo A-I and apo A-II were observed.
These findings confirm the published observations with
other MS approaches than SELDI-TOF MS [30,31]. When
using the anti A-II capture a less intense apo A-I and a
more intense apo A-II peak could be observed whereas in
the anti A-II capture the pattern was the reverse. Further-
more, as indicated in the highlighted areas, (Fig. 5) also
differences in the obtained fingerprints could be
observed, which were HDL capture approach dependent.
The most detailed fingerprint was observed up to 50 kDa;
approximately 95 peaks were detected in the 3–50 kDa
molecular mass range. Between 50 and 160 kDa, 27 more
peaks were detected. A linear normalized plot (Fig. 6) of
the complete spectrum demonstrates an overview of all
detected peaks of both capture types. Notably at least in 5
regions of the spectrum, capture dependent differences
(approximately 33% of the total spectrum) could be observed. This indicates that the used approach identified
two similar but distinct HDL pools depending on the cap-
ture antibody.
Discussion
It has been recognised that HDL is a carrier of a large
number of proteins with variable binding affinities [21].
In this study, a proteomic approach was used exploiting
the potential of SELDI TOF MS as a high-throughput
screening tool for HDL profiling. Immuno-capturing of
HDL in combination with subsequent mass-spectrometry
analysis has been validated as a tool for HDL fingerprint-
ing. Capturing of HDL on the protein chips was found to
be reproducible. Depending on the capture (anti-apo A-I
or A-II) antibody, differences in HDL subpopulations
were revealed in the SELDI-TOF ms fingerprints.
The wash stringency between the different incubation
steps highly influenced the outcome of the fingerprint.
Here, the selected wash stringency was optimized by the
use of Tween-20 in the final wash step to reduce non-spe-
cific binding. This resulted in minor albumin contamina-
tion. Furthermore, only the capture antibody IgG,
coupled onto the SELDI protein-chip, and not plasma IgG
could be detected even in the case when very high laser
intensities were used (>220 relative units). It can be con-
Fingerprints of plasma HDL captured on a PS20 protein-chipigu e 5
Fingerprints of plasma HDL captured on a PS20 pro-
tein-chip. Shown are the HDL fingerprints captured from 
plasma with monoclonal antibodies against apo A-I (Upper 
panel) or apo A-II (Lower panel). A molecular range up to 80 
kDa is presented using different magnifications of the intensi-
ties as indicated for the three mass ranges. The apo A-I pro-
tein peak is observed at 28 kDa. Insert: An extra 2.5 
magnification of native apolipoprotein A-II (17 kDa) as 
detected by SELDI-TOF MS.* corresponds with m/z of mon-
omeric apo A-II. † corresponds with the apo C III.





























Analysis of Apo A-II isoforms in a normal individualFigure 4
Analysis of Apo A-II isoforms in a normal individual. 
The M/Z mass ratios of the three isoforms of apo A-II are 
indicated in the peaks after HDL capture by anti-apo A-II 
antibodies (see material and methods). The mean mass differ-
ences between the peaks are indicated as ∆Mw. The amino 
acid sequence of apo A-II is indicated at the bottom in which 
the "end"-terminal glutamine residues have been indicated in 
bold.
QAKEPCV ESLVSQYFQT VTDYGKDLME KVKSPELQAE  
AKSYFEKSKE QLTPLIKKAG TELVNFLSYF VELGTQPATQ












∆ Mw (Da) 122 (± 8) 132 (± 13)
254 (± 17)
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Gln 2x∆ Mw (Da) 
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HDL particles prior to the protein profiling.
Specificity of the capturing procedure was demonstrated
in 5 ways: 1. The used antibodies captured apo A-I and
apo A-II containing particles as demonstrated in Figures 2
and 3. The 28 kDa peak represents apo A-I and the 17 kDa
represents the dimeric form of apo A-II [30,32]; 2. Captur-
ing with anti-apo A-I or A-II antibodies resulted in compa-
rable fingerprints; 3. HDL pre-purified by gel filtration or
captured from plasma revealed comparable fingerprints.
Only a variation in intensity of the peaks was observed
which was probably due to different levels of the total par-
ticle load on the SELDI-chip; 4. LDL exposed to the pro-
tein chips showed no "HDL" specific profile; 5. the highly
abundant proteins in plasma (albumin and IgG) could
not or hardly be detected in the fingerprints whereas the
most detailed fingerprint was observed in the low mass
range of the spectrum. Analysis of HDL previously con-
firmed the presence of a complex range of small peptides
in the mass range from 1000 to 5000 M/Z [33].
These lines of evidence suggested that the capturing of
HDL from plasma on a SELDI chip with antibodies is a
robust and specific procedure without appreciable con-
tamination from plasma components and other lipopro-
teins.
Additional evidence confirming that the integrity of the
HDL particle was maintained during the capture proce-
dure, was the presence of dimeric apo A-II (Fig. 4). This is
in concordance with previous findings using other MS
approaches [30,34]. From these observations it can be
concluded that the obtained profiles were an outcome of
captured native HDL particles onto the SELDI chip. Our
proteomic profiling demonstrated that the dimeric form
of apo A-II consisted of three species (Fig. 4). These iso-
forms were observed due to the absence of probably one
or two C- terminal glutamine residue per dimer and is in
concordance with findings of others who have used a dif-
ferent proteomic approach [30]. This clearly proved the
feasibility of SELDI-TOF MS to discriminate between apo
A-II isoforms on amino acid level. We therefore propose
that the obtained resolution by this profile approach also
might be useful for the identification of isoforms in other
HDL associated proteins.
Normalized plot of the spectra of two HDL capture typesFigure 6
Normalized plot of the spectra of two HDL capture types. Spectra were obtained after capture of HDL from plasma of 
4 healthy individuals. The highlighted areas show capture-type dependent differences between the apo A-I (Lp A-I) and apo A-
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ies, slight differences between the profiles could be
observed (Fig 6). Specifically in the most sensitive meas-
urable mass range up to 80.000 M/Z SELDI TOF MS could
be used for discrimination of HDL subtypes and could be
a useful extension to the currently available analysis tools
for protein composition of HDL.
The most striking aspect of the protein chip approach is
that the preparation of the HDL consumes a minimum of
time compared to the classic preparation techniques for
lipid preparation e.g. ultracentrifugation, native gel elec-
trophoresis or gel filtration. Moreover, in order to obtain
a detailed fingerprint of the HDL associated proteins
SELDI-TOF MS is much less labour intensive and much
lower in sample consumption compared to other pro-
teomic approaches. We are aware that there are some lim-
itations for this approach. SELDI-TOF ms as such is not a
approach for direct protein identification, but as marker
search this approach has high potential. Moreover, due to
the defined wash stringency one should keep in mind that
an under- or over- estimation of the total HDL proteome
may occur. Particularly in case of higher dilution of
plasma samples, markers of minor abundant HDL sub-
fractions might be lost. This proposed approach might
despite the selective "plasma proteomics" be of more
value compared to complete plasma proteomics. Now,
work is in progress to investigate whether HDL protein
fingerprinting could be a suitable tool in early diagnosis
of patients at high atherothrombotic risk followed by
steps towards protein identification.
We conclude that SELDI-TOF mass-spectrometry offers a
high throughput approach to study HDL composition.
Our goal for future studies is to determine whether
changes in HDL protein composition contribute to
atherothrombotic events. In addition, identification of
HDL protein components could also lead to the discovery
of new biomarkers for the diagnosis and early detection of
atherosclerotic diseases and may contribute to the devel-
opment of more effective therapeutic strategies.
Methods
Sample collection
For lipoprotein measurements, blood was collected in
non-additive or EDTA (10 mM final) containing vacu-
tainer tubes (Becton Dickinson, Mountain View, CA)
from healthy volunteers. For the determination of the
inter and Intra CV of the HDL capture a plasma pool of
more than 200 people was used. The individual variation
(normal variation) was determined in 20 subjects having
normal HDL levels with respect to apo A-I and cholesterol
content. Plasma was prepared and stored at -80°C until
batch-wise assessment. Monoclonal antibodies (anti apo
A-I and A-II), specific for the capture of native HDL-parti-
cles containing apo A-I or apo A-II [35,36], were obtained
from Acris GmbH (Hiddenhausen, Germany) and from
dr. J Fruchard, University of Lille, France. As determined
by surface plasmon resonance, dissociation of HDL from
the antibodies against apo A-I and apo A-II appeared to be
negligible (Kd < 10-5 s-1).
Preparative isolation of lipoproteins by Fast Performance 
Liquid Chromatography
Lipoprotein fractions were isolated from 100 µl plasma
samples by size-exclusion chromatography using a Super-
ose 6 HR 10/30 (Pharmacia Biotech, Uppsala, Sweden)
column at a flow rate of 0.3 ml/min with inline fluores-
cence and UV detection [37]. VLDL, LDL and HDL con-
taining fractions were collected and concentrated with
Centricon-100 (Beverley, MA, USA) concentrator filters to
a final volume of 100 µl. Samples were used immediately
or frozen in liquid nitrogen and stored at -80°C.
Cholesterol analysis (FPLC)
Cholesterol concentrations in the main lipoprotein
classes (VLDL, LDL and HDL) were determined using high
performance gel filtration chromatography (HPGC) as
described elsewhere [38]. Total cholesterol was deter-
mined by PAP 250 cholesterol enzymatic methods
(Biomerieux, Le Fontanille, France). Commercially avail-
able lipid plasma standards (low, medium and high) were
used for total cholesterol quantitative analysis (SKZL,
Nijmegen, the Netherlands) of FPLC separated lipopro-
teins.
Sample preparation and SELDI-TOF MS analysis
Coating of antibodies
A 5 µL mixture containing 2.8 nM anti-apo A-I or A-II
monoclonal antibodies, 3 µM ethylenediamine and 0.1 M
Na2SO4 was added per spot of a PS-20 protein chip
(Ciphergen Biosystems, Fremont, CA, USA) and covalent
binding of antibodies through primary amine-epoxide
chemistry was achieved by incubating the chip in a humid
chamber overnight at 4°C. Excess antibody was removed
by 1 wash with distilled water and subsequently free
amine-binding places were blocked by incubating the
chip for 30 min at room temperature with 1 M Tris buffer
(pH 8.0).
HDL capture
After mounting the PS-20 protein chip(s) in a 96 wells
bioprocessor, 100 µL diluted plasma aliquots (1:2 diluted
with Tris Buffered Saline pH 7.4) or purified HDL were
applied onto single SELDI spots and were allowed to bind
for 2 hours at room temperature on a horizontal shaker.
The protein chips were washed 4 times with TBS for 10
minutes, followed by a 5 minutes TBS-Tween (0.005%)
rinse unless indicated otherwise. A final wash step with
Hepes solution (5 mM) was carried out to remove thePage 6 of 8
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Proteome Science 2007, 5:15 http://www.proteomesci.com/content/5/1/15excess of salt. All spots were allowed to dry and subse-
quently 1.2 µL sinapinic acid (10 mg/ml) in a 50/49.9/0.1
% acetonitril/H2O/trifluoric-acid mix was applied on each
spot. All chips were air dried and stored at room tempera-
ture in the dark. The binding capacity of the coated chips
was approximately 5–10% of the total HDL pool present
in plasma of normal individuals resulting in the chip sur-
face to be the limiting step in the capture procedure.
SELDI-TOF analysis
Analysis was carried out using a PBS IIc protein chip
reader (Ciphergen Biosystems) using an automated data
collection protocol within the Protein-Chip Software (ver-
sion 3.1). Data were collected up to 200 kDa. Laser inten-
sity was set in a range from 190 to 220 relative units and
the focus mass was set to either 17 kDa in case of anti A-II
or 28 kDa in case of anti A-I capture and in some cases an
automatic center focus mass was used. Measurement of
the spectra was performed with approximately 100 shots
at 13 positions per SELDI spot. Calibration was done
using a protein calibration chip (Ciphergen). Spectra were
normalised on total ion current. Detected peaks having a
signal/noise ratio > 5 were recognized as significant peaks.
Differences between capture by apo A-I and apo A-II anti-
bodies was assessed by student's t-test.
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